Acceleron Pharma Inc. (XLRN)

35.91
1.35 3.62
NASDAQ : Health Technology
Prev Close 37.26
Open 37.02
Day Low/High 35.78 / 37.51
52 Wk Low/High 24.37 / 46.93
Volume 362.18K
Avg Volume 292.20K
Exchange NASDAQ
Shares Outstanding 45.42M
Market Cap 1.70B
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acceleron Reports Fourth Quarter And Full Year 2017 Operating And Financial Results

Acceleron Reports Fourth Quarter And Full Year 2017 Operating And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial...

Acceleron To Webcast Fourth Quarter And Full Year 2017 Operating And Financial Results On February 27, 2018

Acceleron To Webcast Fourth Quarter And Full Year 2017 Operating And Financial Results On February 27, 2018

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.

Sujay Kango Named Chief Commercial Officer, Acceleron Pharma Inc.

Sujay Kango Named Chief Commercial Officer, Acceleron Pharma Inc.

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of commercial industry...

Acceleron To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Acceleron To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that members of the management team...

Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy

Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced positive preliminary results for the...

Acceleron Announces Planned Retirement Of Chief Medical Officer, Dr. Matthew L. Sherman

Acceleron Announces Planned Retirement Of Chief Medical Officer, Dr. Matthew L. Sherman

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the planned retirement of Executive Vice...

Acceleron To Webcast Presentation At The 36th Annual J.P. Morgan Healthcare Conference

Acceleron To Webcast Presentation At The 36th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and...

Interesting XLRN Put And Call Options For August 2018

Interesting XLRN Put And Call Options For August 2018

Investors in Acceleron Pharma, Inc. saw new options begin trading this week, for the August 2018 expiration.

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes At The 59th Annual Meeting Of The American Society Of Hematology

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes At The 59th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing...

Acceleron To Host Conference Call And Webcast To Review Data Presented At The 59th American Society Of Hematology Annual Meeting And Exposition

Acceleron To Host Conference Call And Webcast To Review Data Presented At The 59th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma Inc. (NASDAQ:XLRN) will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.

Acceleron Announces Appointment Of Dr. Karen Smith To Its Board Of Directors And Departure Of Terrance McGuire

Acceleron Announces Appointment Of Dr. Karen Smith To Its Board Of Directors And Departure Of Terrance McGuire

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the appointment of the experienced biopharmaceutical executive, Karen Smith, M.

Acceleron Announces Preclinical Results In Pulmonary Arterial Hypertension At The American Heart Association 2017 Scientific Sessions

Acceleron Announces Preclinical Results In Pulmonary Arterial Hypertension At The American Heart Association 2017 Scientific Sessions

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced new preclinical results with sotatercept...

Notable Tuesday Option Activity: XLRN, SHLD, Z

Notable Tuesday Option Activity: XLRN, SHLD, Z

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acceleron Pharma, Inc. , where a total volume of 1,654 contracts has been traded thus far today, a contract volume which is representative of approximately 165,400 underlying shares (given that every 1 contract represents 100 underlying shares).

Acceleron Pharma Reports Third Quarter 2017 Operational And Financial Results

Acceleron Pharma Reports Third Quarter 2017 Operational And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial...

Acceleron To Present Clinical Presentations At The 59th American Society Of Hematology Annual Meeting And Exposition

Acceleron To Present Clinical Presentations At The 59th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts have been accepted...

Acceleron To Webcast Third Quarter 2017 Financial Results On November 7, 2017

Acceleron To Webcast Third Quarter 2017 Financial Results On November 7, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, November 7, 2017 at 8:00 a.

Acceleron Pharma Stock Sees Short Interest Expand By 29.3%

Acceleron Pharma Stock Sees Short Interest Expand By 29.3%

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 826,697 share increase in total short interest for Acceleron Pharma, Inc. , to 3,647,870, an increase of 29.30% since 09/29/2017.

Short Interest In Acceleron Pharma Moves 27% Lower

Short Interest In Acceleron Pharma Moves 27% Lower

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,041,903 share decrease in total short interest for Acceleron Pharma, Inc. , to 2,821,173, a decrease of 26.97% since 09/15/2017.

Acceleron Announces Closing Of Underwriters' Option To Purchase Additional Shares

Acceleron Announces Closing Of Underwriters' Option To Purchase Additional Shares

Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it has issued 810,810 shares...

Acceleron Announces Pricing Of Public Offering Of Common Stock

Acceleron Announces Pricing Of Public Offering Of Common Stock

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today...

Acceleron Announces Proposed Public Offering Of Common Stock

Acceleron Announces Proposed Public Offering Of Common Stock

Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today...

Acceleron Showcases Vision And Strategy At 2017 R&D Day

Acceleron Showcases Vision And Strategy At 2017 R&D Day

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, hosted its Research and Development (R&D) Day in New...

Acceleron To Develop Sotatercept In Pulmonary Arterial Hypertension

Acceleron To Develop Sotatercept In Pulmonary Arterial Hypertension

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it has amended the sotatercept...

Acceleron To Host Research And Development Day On September 19, 2017

Acceleron To Host Research And Development Day On September 19, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will webcast a live presentation from its Research and Development (R&D) Day on Tuesday, September 19, 2017.

Acceleron Announces Publication Of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results In The Lancet Oncology

Acceleron Announces Publication Of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results In The Lancet Oncology

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, announced that The...

XLRN Crosses Above Average Analyst Target

XLRN Crosses Above Average Analyst Target

In recent trading, shares of Acceleron Pharma, Inc. have crossed above the average analyst 12-month target price of $37.40, changing hands for $38.76/share.

Acceleron Pharma Reports Second Quarter 2017 Operational And Financial Results

Acceleron Pharma Reports Second Quarter 2017 Operational And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

Acceleron Announces First Patient Treated In Phase 2 Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Announces First Patient Treated In Phase 2 Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

TheStreet Quant Rating: D (Sell)